Targeting B Cells to Modify MS, NMOSD, and MOGAD: Part 1.
Targeting B Cells to Modify MS, NMOSD, and MOGAD: Part 1.
复制标题
DOI：
10.1212/nxi.0000000000000918
复制
发表时间：
2021-01
期刊：
影响因子：
--
通讯作者：
Hartung HP
中科院分区：
文献类型：
--
作者：
Graf J;Mares J;Barnett M;Aktas O;Albrecht P;Zamvil SS;Hartung HP
Ocrelizumab、利妥昔单抗、ofatumumab、ublituximab、inebilizumab和evobrutinib是靶向各种B细胞相关蛋白的免疫疗法。这些治疗中的大多数已被证明对复发和进展形式的MS和视神经肌萎缩症谱系疾病（NMOSD）有效，或者处于临床开发的晚期。目前，ocrelizumab、ofatumumab和inebilizumab分别被许可用于治疗MS和NMOSD。本文重点介绍有关B淋巴细胞在免疫介导的病理生理学中的作用及其对作用方式的影响的当前知识状况。为了了解这一突破的意义，在目前的MS治疗设备的背景下，这篇综述更密切地研究了CD20耗竭的临床发展和利妥昔单抗的开创性贡献。将重点介绍III期和最近发表的上市后研究，以更好地了解长期B细胞耗竭的相关疗效数据和安全性方面。
Ocrelizumab, rituximab, ofatumumab, ublituximab, inebilizumab, and evobrutinib are immunotherapies that target various B cell–related proteins. Most of these treatments have proven efficacy in relapsing and progressive forms of MS and neuromyelitis optica spectrum disease (NMOSD), or are in advanced stages of clinical development. Currently, ocrelizumab, ofatumumab, and inebilizumab are licensed for treatment of MS and NMOSD, respectively. This review focuses on the current state of knowledge about the role of B lymphocytes in immune-mediated pathophysiology and its implications for the mode of action. To understand the significance of this breakthrough in the context of the current MS therapeutic armamentarium, this review more closely examines the clinical development of CD20 depletion and the pioneering contribution of rituximab. Phase 3 and the recently published postmarketing studies will be highlighted to better understand the relevant efficacy data and safety aspects of long-term B-cell depletion.